MarketMoodz
Lilly tops Q4, lifts 2026 outlook as GLP-1 demand powers growth
Eli Lilly topped Q4 2025 results and raised its 2026 guidance, underscoring the resilience of GLP-1 demand from Zepbound and Mounjaro. Q4 adjusted EPS was $7.54 on $19.29 billion in revenue, and Lilly now sees 2026 revenue of $80-83 billion with adjusted EPS of $33.50-35.
Key Takeaways
- Q4 2025 adjusted EPS of $7.54 and revenue of $19.29B.
- 2026 guidance calls for $80-83B revenue and $33.50-35 EPS.
- GLP-1 growth driven by Zepbound and Mounjaro; Novo Nordisk faces headwinds from price pressure and exclusivity expiries.
- Orforglipron, Lilly's oral GLP-1 candidate, could see an FDA filing later in 2026.
People Involved
- Dave RicksChief Executive Officer, Eli Lilly and Co
Entities Involved
- Eli Lilly and CoPharmaceutical company
- Novo NordiskPharmaceutical company
MarketMoodz Analysis
Lilly's quarterly beat and aggressive 2026 guidance underscore momentum in the fast-growing GLP-1 space, with the company banking on volume-driven gains from Zepbound and Mounjaro to offset pricing pressure and payer dynamics. The 2026 revenue target of $80-83B and EPS of $33.50-35 imply meaningful upside if GLP-1 demand remains robust, and the print compared with analysts' consensus—a 2026 revenue of about $77.6B and EPS around $33.23—suggests Lilly is guiding above the street.
Novo Nordisk faces countervailing pressures as U.S. price declines and exclusivity expiries temper growth, even as a strong U.S. Wegovy launch adds competitive intensity. The broader GLP-1 landscape remains highly strategic for investors, with Orforglipron potentially expanding Lilly's options and policy and payer dynamics likely to shape margins and pricing over the next 12-18 months.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial